Toward the end of trading Tuesday, the Dow traded up 0.80% to 32,058.42 while the NASDAQ rose 4.1% to 13,125.82. The S&P also rose, gaining 2.04% to 3,899.13.
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 20,045,440 cases with around 525,810 deaths. India confirmed a total of at least 11,244,780 confirmed cases and 157,930 deaths, while Brazil reported over 11,051,660 COVID-19 cases with 266,397 deaths. In total, there were at least 117,206,910 cases of COVID-19 worldwide with over 2,601,400 deaths, according to data compiled by Johns Hopkins University.
Leading and Lagging Sectors
Consumer discretionary shares rose 4.4% on Tuesday. Meanwhile, top gainers in the sector included Arcimoto, Inc. FUV, up 25%, and Niu Technologies NIU, up 24%.
In trading on Tuesday, energy shares fell 1.1%.
Top Headline
Dicks Sporting Goods Inc DKS reported better-than-expected results for its fourth quarter, but issued weak earnings forecast for FY21.
Dick's Sporting posted quarterly adjusted earnings of $2.43 per share, exceeding analysts’ estimates of $2.28 per share. The company’s sales came in at $3.13 billion, versus expectations of $3.07 billion.
DICK'S Sporting said it sees FY21 adjusted EPS of $4.40-$5.20 versus expectations of $5.96. The company expects sales of $9.544 billion-$9.935 billion, versus market estimates of $9.53 billion.
Equities Trading UP
INVO Bioscience, Inc. INVO shares shot up 158% to $8.04 after the company announced an amendment under its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals.
Shares of AnPac Bio-Medical Science Co., Ltd. ANPC got a boost, shooting 38% to $7.97 as the company said it has developed and completed evaluations for its CDA Pro Cancer Detection Sensor.
ReneSola Ltd SOL shares were also up, gaining 34% to $13.42 after Raymond James initiated coverage on the stock with an Outperform rating and announced a $14.5 price target.
Check out these big movers of the day
Equities Trading DOWN
ACADIA Pharmaceuticals Inc. ACAD shares tumbled 48% to $23.80. As part of its ongoing review of ACADIA Pharmaceuticals supplemental new drug application for pimavanserin, the FDA said in a March 3 letter it has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. Various analysts also downgraded the stock.
Shares of Graybug Vision, Inc. GRAY were down 51% to $7.22 after the company reported preliminary topline results from Phase 2b ALTISSIMO trial. Piper Sandler downgraded Graybug Vision from Overweight to Neutral and lowered the price target from $27 to $10.
Stitch Fix, Inc. SFIX was down, falling 29% to $48.68 after the company reported weaker-than-expected sales for its second quarter. The company also said its Q2 net revenue per active client declined 7% year-over-year. Deutsche Bank downgraded the stock from Buy to Hold.
Commodities
In commodity news, oil traded down 1.7% to $63.93, while gold traded up 2.2% to $1,714.50.
Silver traded up 3.3% Tuesday to $26.095 while copper fell 2.1% to $4.0090.
Euro zone
European shares closed higher today. The eurozone’s STOXX 600 climbed 0.76%, the Spanish Ibex Index rose 0.62% and the German DAX 30 gained 0.40%. Meanwhile, the French CAC 40 rose 0.37%, London’s FTSE 100 rose 0.17% and Italy’s FTSE MIB gained 0.57%.
The Eurozone economy contracted by 0.7% in the fourth quarter following a record 12.4% growth in the earlier three-month period. The German current account surplus widened slightly to €16.9 billion in January from €16.6 billion a year ago, while trade surplus rose to €14.3 billion from €13.7 billion.
French payroll employment in the private sector fell 0.1% to 19.4 million during the fourth quarter. Italy's industrial production increased 1% in January following a revised 0.2% rise in December.
Economics
The NFIB small business optimism index rose to 95.8 in February from 95.0 in January.
The Johnson Redbook Retail Sales Index rose 8% year-over-year during the first week of March.
Federal Reserve Bank of Dallas President Robert Kaplan will speak at 6:05 p.m. ET.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
